Karakasis, Paschalis http://orcid.org/0000-0002-3561-5713
Popovic, Djordje S.
Patoulias, Dimitrios
Koufakis, Theocharis
Papanas, Nikolaos
Fragakis, Nikolaos
Rizzo, Manfredi
Article History
Received: 19 November 2023
Accepted: 14 December 2023
First Online: 5 January 2024
Declarations
:
: Djordje S. Popovic declares associations with Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and Wörwag Pharma. Theocharis Koufakis has received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Pharmaserve Lilly, and Novo Nordisk, for advisory boards from Novo Nordisk and Boehringer-Ingelheim, and has participated in sponsored studies by Eli Lilly and Novo Nordisk. Nikolaos Papanas has been an advisory board member of AstraZeneca, Boehringer-Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Elpen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. Manfredi Rizzo is Editorial Board Member of Diabetes Therapy and has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. None of the aforementioned pharmaceutical companies had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.
: This study adhered to the principles of the Cochrane Handbook for systematic reviews [CitationRef removed] and the reporting conformed to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 2020 guidelines [CitationRef removed]. The protocol was prospectively registered on the Open Science Framework (ExternalRef removed) and was adhered to without deviations. As this is a meta-analysis of published RCTs, no ethical approval was required.